ERBB2 and breast carcinoma: Accordingly, current guidelines emphasize escalation strategies for patients with residual invasive disease: capecitabine in TNBC (CREATE-X), T-DM1 in HER2-positive breast cancer (KATHERINE), and perioperative pembrolizumab in TNBC (KEYNOTE-522) [5,6,7].